Skip to main content

Table 8 Summary of studies in which multimodal treatment was performed without dissection of the internal mammary lymph node for patients with breast cancer and internal mammary lymph node metastases

From: Optimal radiotherapy for patients with internal mammary lymph node metastasis from breast cancer

AuthorsNo. of patientsMedian FU (months)Pathologic confirmation of IMN+Chemotherapy regimenMedian IMN RT dose, (range)IMN recurrence5-year survival rates
Zhang et al. (4)96419%AT-based (100%)60.0 Gy (50.0–72.0 Gy)11%DFS 56%, OS 76%
Park et al. (25)1)15380%T-based (73%), A-based (20%)50.4 Gy (50.4–55.8 Gy)6.7%DFS 67%, OS 79%
Noh et al. (26)1)455740%AT (54.5%), AC (29.1%)50.0–50.4 Gy +/− boost0%DFS 66%, OS 76%
Joo et al. (12)705157%T-based (94%)60.0 Gy (56.0–66.0 Gy)2.9%DFS 72%, OS 77%
Sachdev et al. (27)2538Not reportedNot reported50.4 Gy (45.0–64.4 Gy)0%Not reported
Kim et al. (28)95432%Not reported50.0 Gy +/− boost (n = 12)3.2%DFS 70%, OS 84%
The present study845848%T-based (100%)62.5 Gy (50.0–66.5 Gy)2.4%DFS 72%, OS 81%
  1. 1)The studies included patients with internal mammary lymph node or supraclavicular lymph node metastasis from breast cancer
  2. Abbreviations FU Follow-up, IMN+ Metastasis to the internal mammary lymph node, IMN Internal mammary node, RT Radiotherapy, A Adriamycini, T Taxane, DFS Disease-free survival, OS Overall survival